CA2861020C - 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives and their use as cxcr3 receptor modulators - Google Patents

4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives and their use as cxcr3 receptor modulators Download PDF

Info

Publication number
CA2861020C
CA2861020C CA2861020A CA2861020A CA2861020C CA 2861020 C CA2861020 C CA 2861020C CA 2861020 A CA2861020 A CA 2861020A CA 2861020 A CA2861020 A CA 2861020A CA 2861020 C CA2861020 C CA 2861020C
Authority
CA
Canada
Prior art keywords
methyl
benzoimidazol
thiazol
piperazin
ethanone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2861020A
Other languages
English (en)
French (fr)
Other versions
CA2861020A1 (en
Inventor
Eva Caroff
Marcel KELLER
Thierry Kimmerlin
Emmanuel Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48014121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2861020(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CA2861020A1 publication Critical patent/CA2861020A1/en
Application granted granted Critical
Publication of CA2861020C publication Critical patent/CA2861020C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2861020A 2012-02-02 2013-02-01 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives and their use as cxcr3 receptor modulators Active CA2861020C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2012/050489 2012-02-02
IBPCT/IB2012/050489 2012-02-02
PCT/IB2013/050870 WO2013114332A1 (en) 2012-02-02 2013-02-01 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives

Publications (2)

Publication Number Publication Date
CA2861020A1 CA2861020A1 (en) 2013-08-08
CA2861020C true CA2861020C (en) 2018-07-17

Family

ID=48014121

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2861020A Active CA2861020C (en) 2012-02-02 2013-02-01 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives and their use as cxcr3 receptor modulators

Country Status (20)

Country Link
US (1) US9266876B2 (cg-RX-API-DMAC7.html)
EP (1) EP2809668B1 (cg-RX-API-DMAC7.html)
JP (1) JP6073931B2 (cg-RX-API-DMAC7.html)
KR (1) KR101800607B1 (cg-RX-API-DMAC7.html)
CN (1) CN104093715B (cg-RX-API-DMAC7.html)
AU (1) AU2013216354B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014018714A8 (cg-RX-API-DMAC7.html)
CA (1) CA2861020C (cg-RX-API-DMAC7.html)
CL (1) CL2014002048A1 (cg-RX-API-DMAC7.html)
EA (1) EA027595B1 (cg-RX-API-DMAC7.html)
ES (1) ES2632237T3 (cg-RX-API-DMAC7.html)
IL (1) IL233872A (cg-RX-API-DMAC7.html)
MX (1) MX352181B (cg-RX-API-DMAC7.html)
MY (1) MY170524A (cg-RX-API-DMAC7.html)
NZ (1) NZ629795A (cg-RX-API-DMAC7.html)
PH (1) PH12014501540A1 (cg-RX-API-DMAC7.html)
PL (1) PL2809668T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201404144PA (cg-RX-API-DMAC7.html)
UA (1) UA113638C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013114332A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201807959T4 (tr) * 2013-07-22 2018-06-21 Idorsia Pharmaceuticals Ltd 1-(Piperazın-1-il)-2- ([1,2,4] triazol-1-il)-etanon türevleri.
JP6510539B2 (ja) 2014-01-09 2019-05-08 ザ ジェイ. デヴィッド グラッドストーン インスティテューツ, ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ. デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物
AR099789A1 (es) * 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR103399A1 (es) * 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
RS58349B1 (sr) * 2015-01-15 2019-03-29 Idorsia Pharmaceuticals Ltd Hidroksialkil-piperazinski derivati kao modulatori cxcr3 receptora
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2018011265A1 (en) 2016-07-13 2018-01-18 Idorsia Pharmaceuticals Ltd Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
FR3067028B1 (fr) 2017-06-06 2019-07-12 Adpuerivitam Modulateurs de recepteurs nmda, compositions les comprenant et utilisation de ces composes dans le traitement de maladies impliquant le systeme nerveux central
AU2021324684A1 (en) * 2020-08-11 2023-04-20 Board Of Trustees Of Michigan State University Proteasome enhancers and uses thereof
EP4228632A4 (en) * 2020-10-16 2025-02-19 Saint Louis University Rev-erb agonists

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523530A (ja) 2001-01-23 2004-08-05 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしてのピペラジンおよびピペリジン誘導体
EP1363898A4 (en) 2001-03-02 2004-12-08 Bristol Myers Squibb Co COMPOUNDS SUITABLE AS MODULATORS OF MELANOCORTIN RECEPTORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
GB0315203D0 (en) 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
AU2004293026B2 (en) 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
US20060276465A1 (en) 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
JP2008530216A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Cxcr3アンタゴニスト活性を有する、複素環で置換された新規のピリジンまたはフェニル化合物
AU2006214378A1 (en) 2005-02-16 2006-08-24 Pharmacopeia, Inc. Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
CN101163692B (zh) 2005-02-16 2012-01-18 先灵公司 具有cxcr3拮抗活性的杂环取代的哌嗪
US7566718B2 (en) 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
CN101189238A (zh) 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶
WO2006091428A2 (en) 2005-02-16 2006-08-31 Schering Corporation Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity
CA2598458A1 (en) 2005-02-16 2006-08-24 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
ES2430569T3 (es) * 2005-02-18 2013-11-21 Astrazeneca Ab Compuestos antibacterianos derivados de piperidina
US20080312215A1 (en) 2005-06-28 2008-12-18 Pharmacopeia Drug Discovery, Inc. Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
EP1937666B1 (en) 2005-10-11 2012-02-22 Schering Corporation Substituted heterocyclic compounds with cxcr3 antagonist activity
US20090143413A1 (en) * 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
EP1962605A2 (en) * 2005-12-12 2008-09-03 Merck & Co., Inc. 2-arylthiazole derivatives as cxcr3 receptor modulators
WO2007076318A2 (en) 2005-12-21 2007-07-05 Smithkline Beecham Corporation Camphor-derived cxcr3 antagonists
EP1988900A2 (en) 2006-02-23 2008-11-12 Merck & Co., Inc. Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators
PE20071144A1 (es) 2006-03-21 2008-01-10 Schering Corp COMPUESTOS HETEROCICLICOS DE PIRIDINA SUSTITUIDA COMO ANTAGONISTAS DEL RECEPTOR 3 DE a-QUIMIOCINA (CXCR3)
FR2903405B1 (fr) 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
AR061975A1 (es) 2006-07-14 2008-08-10 Schering Corp Compuestos de piperazina 1,4-sustituida con actividad antagonista de cxcr3, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de quimioquina cxcr3
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
CN101558066A (zh) * 2006-08-17 2009-10-14 阿斯利康(瑞典)有限公司 具有抗菌活性的吡咯衍生物
EP2094688A1 (en) 2006-12-22 2009-09-02 Schering Corporation Heterocyclic compounds with cxcr3 antagonist activity
CA2669412A1 (en) 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
PL2121660T3 (pl) 2007-01-25 2015-06-30 Du Pont Amidy grzybobójcze
JP2010535711A (ja) 2007-08-03 2010-11-25 シェーリング コーポレイション 複素環式置換ピペラジンを用いる、cxcr3媒介性疾患の処置方法
TWI428091B (zh) 2007-10-23 2014-03-01 Du Pont 殺真菌劑混合物
EP2234971A1 (en) 2007-12-18 2010-10-06 Schering Corporation Process and intermediates for the synthesis of heterocyclic substituted piperazines with cxcr3 antagonist activity
EP2242757B1 (en) * 2008-01-09 2012-08-01 Array Biopharma, Inc. Pyrazolopyridines as kinase inhibitors
BRPI0905758A2 (pt) 2008-01-25 2015-07-14 Du Pont Composto, método de controle de doenças de plantas e composição fungicida
EP2402332A3 (en) 2008-01-25 2014-10-29 E.I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
MX2010011879A (es) 2008-04-30 2010-12-06 Bayer Cropscience Ag Esteres y tioesteres del acido tiazol-4-carboxilico como agentes fitoprotectores.
CN102159213B (zh) * 2008-09-11 2015-05-27 凯莫森特里克斯股份有限公司 4-氨基-3-(咪唑基)-吡唑并[3,4-b]嘧啶
KR20110067052A (ko) 2008-10-01 2011-06-20 바이엘 크롭사이언스 아게 식물 보호제로서의 헤테로사이클릴 치환된 티아졸
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
US8618137B2 (en) 2008-12-02 2013-12-31 E I Du Pont De Nemours And Company Fungicidal heterocyclic compounds
BRPI0923366A2 (pt) 2008-12-11 2019-09-24 Bayer Cropscience Ag éteres e hodrazonas de oxima de tiazolila como agentes protetors de culturas.
JP5807971B2 (ja) * 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cxcr3受容体アンタゴニスト
US8362249B2 (en) 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
EP2272846A1 (de) 2009-06-23 2011-01-12 Bayer CropScience AG Thiazolylpiperidin Derivate als Fungizide
AU2010283832A1 (en) 2009-08-12 2012-02-23 Syngenta Participations Ag Microbiocidal heterocycles
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
WO2011051243A1 (en) 2009-10-29 2011-05-05 Bayer Cropscience Ag Active compound combinations
CN102712634B (zh) 2009-10-30 2016-04-06 拜耳知识产权有限责任公司 杂芳基哌啶和杂芳基哌嗪衍生物
WO2011076699A1 (de) 2009-12-21 2011-06-30 Bayer Cropscience Ag Bis(difluormethyl)pyrazole als fungizide
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
BR112012027762B1 (pt) 2010-04-28 2018-06-05 Bayer Intellectual Property Gmbh Derivados de cetoheteroarilpiperidina e - piperazina como fungicidas
US8815775B2 (en) 2010-05-18 2014-08-26 Bayer Cropscience Ag Bis(difluoromethyl)pyrazoles as fungicides
EP2571866A1 (en) 2010-05-20 2013-03-27 E.I. Du Pont De Nemours And Company Fungicidal oximes and hydrazones
JP2013528169A (ja) 2010-05-27 2013-07-08 バイエル・クロップサイエンス・アーゲー 殺菌剤としてのピリジニルカルボン酸誘導体
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
EP2632922B1 (de) 2010-10-27 2019-02-27 Bayer CropScience Aktiengesellschaft Heteroarylpiperidin und -piperazinderivate als fungizide
EP2643312B1 (en) 2010-11-25 2014-09-10 Syngenta Participations AG Microbicidal heterocycles
KR20140017520A (ko) 2010-12-17 2014-02-11 이 아이 듀폰 디 네모아 앤드 캄파니 살진균제 아조사이클릭 아미드
WO2012104273A1 (de) 2011-02-01 2012-08-09 Bayer Cropscience Ag Heteroarylpiperidin und -piperazinderivate als fungizide
BR112013020419A2 (pt) 2011-02-10 2016-07-12 Syngenta Participations Ag microbicidas derivados de pirazol
US8748432B2 (en) 2011-02-10 2014-06-10 Syngenta Participations Ag Microbiocidal pyrazole derivatives
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US10004232B2 (en) 2011-09-15 2018-06-26 Bayer Intellectual Property Gmbh Piperidine pyrazoles as fungicides
BR112014009037A2 (pt) 2011-10-18 2017-05-09 Syngenta Participations Ag derivados pirazol microbicidas
BR112014009086A2 (pt) 2011-10-18 2017-05-09 Syngenta Participations Ag derivados pirazol microbicidas
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
WO2013127808A1 (en) 2012-03-02 2013-09-06 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2013127784A1 (en) 2012-03-02 2013-09-06 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014062938A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Rory modulators
WO2014075874A1 (en) 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014075873A1 (en) 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives

Also Published As

Publication number Publication date
EA027595B1 (ru) 2017-08-31
WO2013114332A1 (en) 2013-08-08
KR101800607B1 (ko) 2017-11-23
JP2015506957A (ja) 2015-03-05
IL233872A (en) 2017-05-29
MX2014009355A (es) 2014-09-01
CN104093715A (zh) 2014-10-08
US9266876B2 (en) 2016-02-23
PH12014501540B1 (en) 2014-09-22
SG11201404144PA (en) 2014-10-30
UA113638C2 (xx) 2017-02-27
CN104093715B (zh) 2017-04-26
NZ629795A (en) 2016-06-24
EP2809668A1 (en) 2014-12-10
EA201400854A1 (ru) 2015-04-30
PH12014501540A1 (en) 2014-09-22
MY170524A (en) 2019-08-09
CA2861020A1 (en) 2013-08-08
KR20140120364A (ko) 2014-10-13
JP6073931B2 (ja) 2017-02-01
EP2809668B1 (en) 2017-04-12
MX352181B (es) 2017-11-13
HK1203939A1 (en) 2015-11-06
PL2809668T3 (pl) 2018-02-28
AU2013216354B2 (en) 2017-08-31
BR112014018714A2 (cg-RX-API-DMAC7.html) 2017-06-20
CL2014002048A1 (es) 2014-11-14
BR112014018714A8 (pt) 2017-12-26
AU2013216354A1 (en) 2014-09-25
US20140371204A1 (en) 2014-12-18
ES2632237T3 (es) 2017-09-12

Similar Documents

Publication Publication Date Title
AU2013216354B2 (en) 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
US11739098B2 (en) Substituted indole compounds
KR102473482B1 (ko) [1,2,4]트리아졸로[1,5-a]피리디닐 치환된 인돌 화합물
CN113166139A (zh) 作为HPK1抑制剂的吡咯并[2,3-b]吡啶及其用途
RS53500B1 (sr) Supstituisana jedinjenja n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-karboksamida kao cfms inhibitori
WO2011072694A1 (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
AU2015237826A1 (en) 8-(Piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives
CA3194376A1 (en) Hsd17b13 inhibitors and uses thereof
CN118414336A (zh) 通过使布鲁顿酪氨酸激酶(btk)抑制剂与e3连接酶配体缀合来降解btk及使用方法
CN117836297A (zh) (s)-1-(5-((吡啶-3-基)硫代)吡嗪-2-基)-4'h,6'h-螺[哌啶-4,5'-吡咯并[1,2-b]吡唑]-4'-胺衍生物和类似化合物作为shp2抑制剂用于例如癌症的治疗
CA3236550A1 (en) Spirotricycle ripk1 inhibitors and methods of uses thereof
CA3117510A1 (en) 5-azaindazole derivatives as adenosine receptor antagonists
HK1203939B (en) 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
HK40121516A (en) Sulfonyl derivatives as ccr6 inhibitors
TW202435872A (zh) 新穎化合物
CN118488957A (zh) 螺三环ripk1抑制剂及其使用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160524

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250801

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106